Critical Path Institute Introduces Global Initiative 'One to Millions'

Critical Path Institute (C-Path) has announced the launch of 'One to Millions', a global initiative aimed at scaling advanced therapeutic treatments for individualized medicine. This initiative seeks to close the regulatory gap delaying patient access to therapies designed for rare genetic diseases.

The project leverages C-Path's regulatory-grade data platform to support evidence generation and regulatory frameworks. Organizers emphasize the need for standardized manufacturing protocols to address inefficiencies in small-volume drug development. The initiative allows developers to utilize existing knowledge to focus on novel components, thus accelerating regulatory reviews.

Prominent figures, including Julia Vitarello and Janet Woodcock, acknowledge the potential of this coordinated effort to transform therapeutic approaches. The program aims to integrate post-authorization evidence generation for better regulatory and payer assessments, fostering a system of continuous learning.

Participants include significant entities like the n-Lorem Foundation and Mila's Miracle Foundation. Through collaborative data sharing, the initiative could revolutionize how genetic therapies are developed and accessed globally.